- BNF:
- 5.1.8
- Status:
- Red, Green - after consultant/specialist initiation
- Decision Date:
- None
Comments
RED:
- Colobreathe dry powder inhaler, 125mg/capsule. NICE TA276: treating pseudomonas lung infection in cystic fibrosis. (Decision date - April 2013).
- Promixin for cystic fibrosis patients. (Decision date - March 2015).
GREEN after consultant/specialist initiation: see prescribing guidance for nebulised colistimethate injection (Colomycin) in Pseudomonas aeruginosa lung infections in adults with Bronchiectasis (non-Cystic Fibrosis patients). (Decision date - May 2018).
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again